



**NeuroScientific**

BIOPHARMACEUTICALS

ASX:NSB

**ASX ANNOUNCEMENT  
3 DECEMBER 2021**

## INVESTOR WEBINAR PRESENTATION

NeuroScientific Biopharmaceuticals Ltd (**ASX:NSB**) (“**NeuroScientific**” or “**the Company**”) is pleased to announce its participation in the ShareCafe Small Cap “Hidden Gems” Webinar, to be held Friday 3<sup>rd</sup> December 2021 from 12.30pm AEDT / 9.30am AWST.

Director of Operations Alexandra Andrews will provide an overview of the Company’s peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions, in addition to the Company’s recent partnership with leading neuroimaging company Imeka.

This webinar is able to be viewed live via Zoom and will provide viewers the opportunity to hear from, and engage with, a range of ASX-listed leading micro/mid cap companies.

To access further details of the event and to register at no cost, please copy and paste the following link into your internet browser:

[https://us02web.zoom.us/webinar/register/5416151767246/WN\\_yxNAuZ51RWK4k0xE\\_eloeg](https://us02web.zoom.us/webinar/register/5416151767246/WN_yxNAuZ51RWK4k0xE_eloeg)

A recorded copy of the webinar will be made available following the event.

A copy of the investor presentation to be delivered during the webinar is attached.

This announcement is authorised by the board of NeuroScientific Biopharmaceuticals Ltd.

-ENDS-

For more information please contact:

Matthew Liddelow  
CEO and Managing Director  
ml@neuroscientific.com  
+ 61 8 6382 1805

Lucas Robinson  
Investor Relations  
Corporate Storytime  
lucas@corporatestorytime.com  
+ 61 408 228 889

### **About NeuroScientific Biopharmaceuticals Ltd**

NeuroScientific Biopharmaceuticals Limited (ASX: NSB) is a company developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The company’s product portfolio includes EmtinB™, a therapeutic peptide initially targeting Alzheimer’s disease and glaucoma, as well as other Emtin peptides

(EmtinAc, EmtinAn, and EmtinBn) which have demonstrated similar therapeutic potential as EmtinB™. For more information, please visit [www.neuroscientific.com](http://www.neuroscientific.com)


#### **About EmtinB™**

EmtinB™ is a peptide-based compound that binds to surface-based cell receptors from the LDLR family, activating intracellular signalling pathways that stimulate neuroprotection, neuroregeneration and modulate neuroinflammation. EmtinB™ is modelled on a specific active domain of the complex human protein called Metallothionein-IIA, which is produced as part of the human body's innate immune response to cell injury.

Our preclinical research has established that EmtinB™ is highly specific and selective for its target receptor, safe and well tolerated at high concentrations, and is able to penetrate the blood brain barrier. A series of Phase I clinical studies will be conducted to establish the safety profile of EmtinB™ in humans.



# NOVEL DRUG THERAPIES FOR NEURODEGENERATIVE CONDITIONS

Company Presentation  
December 2021



**NeuroScientific**

BIOPHARMACEUTICALS



**NeuroScientific**  
BIOPHARMACEUTICALS

ASX:NSB

---

## DISCLAIMER

The purpose of the presentation is to provide an update of the business of NeuroScientific Biopharmaceuticals Ltd (“NeuroScientific”, or “the Company”). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Further information is available upon request.

The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information. Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside NeuroScientific’s control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and NeuroScientific’s current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution.

This presentation should not be relied on as a recommendation or forecast by NeuroScientific. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.



# COMPANY SNAPSHOT

## NOVEL LEAD COMPOUND

- EmtinB™ - potential first in-class therapeutic for neurodegenerative conditions
- Potential disease modifying therapeutic
- Low potential for off-target effects

## SUBSTANTIAL SAFETY & EFFICACY DATA

- >40 studies completed to date
- Preclinical efficacy data in models of Alzheimer's disease, Multiple Sclerosis, Glaucoma and Spinal Cord Injury.
- Large body of published literature to support MOA

## ADDRESSING UNMET NEED IN NEURODEGENERATION

- Alzheimer's disease – global prevalence 55M<sup>1</sup>, high unmet need
- Multiple Sclerosis – US\$27 billion treatment market<sup>2</sup>, unmet need for progressive MS
- Glaucoma – 76M global prevalence<sup>3</sup>, 2<sup>nd</sup> lead cause of blindness

## WELL FUNDED FOR PHASE 1 PROGRAMS

- Plan to undertake two Phase 1 clinical studies in 2022 – First in Human Phase 1 for Neurology indication and First in Patient Phase 1 for glaucoma
- \$12.3M cash on hand

# CORPORATE OVERVIEW (ASX: NSB)

## CAPITAL STRUCTURE

|                             |        |
|-----------------------------|--------|
| <b>ASX code</b>             | NSB    |
| <b>Shares on issue</b>      | 143.5M |
| <b>Price (02/12/21)</b>     | \$0.35 |
| <b>Market cap</b>           | \$50M  |
| <b>McRae Investments</b>    | 18%    |
| <b>Swiss based fund</b>     | 9.0%   |
| <b>Executive Management</b> | 5.0%   |

## FINANCIALS

- IPO on ASX July 2018 (ASX: NSB)
- ~ \$12.3M cash on hand
- Funded through to completion of current Phase I clinical program
- McRae Investments and AlphaSwiss Partners significant shareholders



---

## LEADERSHIP AND MANAGEMENT



**PAUL RENNIE**, MBM, MSTC  
NON-EXECUTIVE CHAIRMAN

Founding CEO of Paradigm Biopharmaceuticals (ASX:PAR). Former COO and Executive VP New Product Development at Mesoblast Ltd (ASX:MSB).



**MATT LIDDELOW**, MPHARM  
MD + CEO

14+ years experience commercialising medical devices and pharmaceuticals for multi-national companies including AstraZeneca.



**DR ANTON UVAROV**, PhD, MBA  
EXECUTIVE DIRECTOR + CSO

Founding director of Actinogen Medical (ASX:ACW) an advanced Alzheimer's biotechnology company. Former Equities Analyst with Citigroup, US



**STEPHEN QUANTRILL**, MBA  
NON-EXECUTIVE DIRECTOR

20+ years experience in corporate advisory and company directorship, Executive Chairman of McRae Investments.



**ABBY MACNISH**, CFA  
Company Secretary & CFO




**DOUGAL THRING**, MSc  
VP Clinical Development



**DR ALEXANDRA ANDREWS**, PhD  
Director of Operations

# MARKETS

- **Neurodegenerative Disease market** valued at ~USD 39.24 billion in 2020 is expected to witness a revenue of USD 44.90 billion in 2026<sup>1</sup>
- ~ **55 million** people worldwide currently have dementia; Alzheimer's disease affects about **60-70%** of them<sup>2</sup>
- The global Multiple Sclerosis drugs market value is \$27.38 billion in 2021<sup>3</sup>
- The total lifetime costs on individual MS patients exceed \$4 million<sup>4</sup>





# EMTINB™ PRECLINICAL DATA

- Nerve regeneration (including significant results in spinal injury model)
- Reduction in neuroinflammation
- Neuroprotection in cell survival models >90%
- Proliferation of myelin in Multiple Sclerosis model
- Slowed cognitive decline in Alzheimer's disease animal models
- Slowed glaucoma-induced damage to the optic nerve in animal model
- Advanced safety program in animals, including non-human primates






# EMTINB™ DEVELOPMENT PLAN

**2021**

**2022**



**Please note:**

Indicative timeline only and subject to change due to the Company relying on independent contract service providers to perform our research.

# PARTNERS AND COLLABORATIONS

## NON-CLINICAL RESEARCH




## CLINICAL RESEARCH




## MANUFACTURING




## SCIENTIFIC ADVISORY

 **Dr Frank Bonner, PhD FBTS**  
Former Director, Non-clinical R&D, Novartis


 **Prof. Dao-Yi Yu MD FRANZCO**  
Head, Physiology & Pharmacology Research,  
Lions Eye Inst. Australia

 **Clin Prof. Allan Kermode MBBS MD FRACP FRCP**  
Head, Neurology & Neurophysiology, SCG Hospital,  
WA Australia. Head, Demyelinating Disease  
Research, Perron Inst. Australia

 **Dr Peter Hnik, MD MHSc**  
Ophthalmologist, President of Cliniscape  
Consulting, Former Chief Medical Officer of  
ICO Therapeutics Inc. Canada

# SUMMARY OVERVIEW

- Drug development company with advanced preclinical lead candidate - EmtinB™
  - Funded through to completion of Phase I program
  - Potential for multiple treatment indications (pipeline in a product)
  - Peptide based drug with advanced safety program
  - Transitioning EmtinB™ to clinical development in 2022
- **EmtinB™ preclinical data has demonstrated:**
    - Neuroprotection, axonal regeneration, decreased neuroinflammation
    - Regeneration of myelin in Multiple sclerosis model
    - Slowed cognitive decline in Alzheimer's disease
    - Protected & restored optic nerve in glaucoma



## FOR MORE INFORMATION:

**Matt Liddelow**

CEO & Managing Director  
[ml@neuroscientific.com](mailto:ml@neuroscientific.com)

**Alex Andrews**

Director of Operations  
[aa@neuroscientific.com](mailto:aa@neuroscientific.com)

[www.neuroscientific.com](http://www.neuroscientific.com)



**NeuroScientific**  
BIOPHARMACEUTICALS

ASX:NSB